Humanigen: Falls on terminating blood cancer study agreement with Gilead

Humanigen

19/04/2021 17:02

** Drug developer's shares  HGEN.O  fall 6.7% to $13.75
    ** Co terminates clinical collaboration agreement with Kite,
a unit of Gilead Sciences Inc  GILD.O , to study HGEN's lead
drug candidate, lenzilumab, in patients with a type of blood
cancer  urn:newsml:reuters.com:*:nBwc0xK8va
    ** HGEN also reports data from an early-stage clinical trial
showing an objective response rate (ORR) of 100% at recommended
Phase 2 dose of the drug
    ** ORR refers to the percentage of patients whose cancer
shrinks or disappears after treatment
    ** HGEN and Kite had agreed in 2019 to conduct an
early-to-mid stage study of lenzilumab in combination with
GILD's CAR T cell therapy, Yescarta, to treat diffuse large
B-cell lymphoma - the most common type of blood cancer
    ** Stock fell 15.8% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))